These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 366085)

  • 1. Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.
    Bateman DN; Coxon A; Legg NJ; Reid JL
    J Neurol Neurosurg Psychiatry; 1978 Dec; 41(12):1109-13. PubMed ID: 366085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Mackenzie RA; Lance JW
    Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies with bromocriptine. Part 1. "On-off" phenomena.
    Kartznel R; Calne DB
    Neurology; 1976 Jun; 26(6 PT 1):508-10. PubMed ID: 945489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of parkinsonism with bromocriptine.
    Calne DB; Plotkin C; Williams AC; Nutt JG; Neophytides A; Teychenne PF
    Lancet; 1978 Apr; 1(8067):735-8. PubMed ID: 76747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
    Hely MA; Morris JG; Rail D; Reid WG; O'Sullivan DJ; Williamson PM; Genge S; Broe GA
    J Neurol Neurosurg Psychiatry; 1989 Mar; 52(3):324-8. PubMed ID: 2647907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.
    Agid Y; Pollak P; Bonnet AM; Signoret JL; Lhermitte F
    Lancet; 1979 Mar; 1(8116):570-2. PubMed ID: 85162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dosages of bromocriptine added to levodopa in Parkinson's disease.
    Hoehn MM; Elton RL
    Neurology; 1985 Feb; 35(2):199-206. PubMed ID: 3969207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
    Jansen EN
    Eur Neurol; 1978; 17(2):92-9. PubMed ID: 344042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine: low-dose therapy in Parkinson disease.
    Teychenne PF; Bergsrud D; Racy A; Elton RL; Vern B
    Neurology; 1982 Jun; 32(6):577-83. PubMed ID: 7201089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
    Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
    Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
    Lees AJ; Katzenschlager R; Head J; Ben-Shlomo Y
    Neurology; 2001 Nov; 57(9):1687-94. PubMed ID: 11706112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study.
    Toyokura Y; Mizuno Y; Kase M; Sobue I; Kuroiwa Y; Narabayashi H; Uono M; Nakanishi T; Kameyama M; Ito H
    Acta Neurol Scand; 1985 Aug; 72(2):157-70. PubMed ID: 3901650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine in Parkinson's disease.
    Ludin HP; Ringwald E; Lörincz P
    Lancet; 1978 Sep; 2(8089):578-9. PubMed ID: 79947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.